Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles
Source abstract
Abstract
Most proteins are hydrophilic and poorly encapsulated into the hydrophobic matrix of solid lipid nanoparticles (SLN). To solve this problem, poly (lactic-co-glycolic acid) (PLGA) was utilized as a lipophilic polymeric emulsifier to prepare hydrophilic protein-loaded SLN by w/o/w double emulsion and solvent evaporation techniques. Hydrogenated castor oil (HCO) was used as a lipid matrix and bovine serum albumin (BSA), lysozyme and insulin were used as model proteins to investigate the effect of PLGA on the formulation of the SLN. The results showed that PLGA was essential for the primary w/o emulsification. In addition, the stability of the w/o emulsion, the encapsulation efficiency and loading capacity of the nanoparticles were enhanced with the increase of PLGA concentration. Furthermore, increasing PLGA concentration decreased zeta potential significantly but had no influence on particle size of the SLN. In vitro release study showed that PLGA significantly affected the initial burst release, i.e. the higher the content of PLGA, the lower the burst release. The released proteins maintained their integrity and bioactivity as confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and biological assay. These results demonstrated that PLGA was an effective emulsifier for the preparation of hydrophilic protein-loaded SLN.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Hu · Int. J. Pharm. · 2004 · 273 · 2910.1016/j.ijpharm.2003.12.016 ↗
2. Müller · J. Biotechnol. · 2004 · 113 · 15110.1016/j.jbiotec.2004.06.007 ↗
3. Lee · Prog. Polym. Sci. · 2007 · 32 · 66910.1016/j.progpolymsci.2007.04.001 ↗
4. Almeida · Adv. Drug Deliv. Rev. · 2007 · 59 · 47810.1016/j.addr.2007.04.007 ↗
5. Halter · J. Control. Release · 2005 · 101 · 20910.1016/j.jconrel.2004.07.002 ↗
6. Stevens · Anticancer Res. · 2003 · 23 · 439
7. Bjerregaard · J. Control. Release · 2001 · 71 · 8710.1016/S0168-3659(00)00370-9 ↗
8. Cui · Int. J. Pharm. · 2002 · 238 · 22910.1016/S0378-5173(02)00079-0 ↗
9. Sinha · J. Control. Release · 2003 · 90 · 26110.1016/S0168-3659(03)00194-9 ↗
10. Müller · Int. J. Pharm. · 1996 · 138 · 8510.1016/0378-5173(96)04539-5 ↗
11. Wissing · Adv. Drug Deliv. Rev. · 2004 · 56 · 125710.1016/j.addr.2003.12.002 ↗
12. Garcia-Fuentes · Int. J. Pharm. · 2005 · 296 · 12210.1016/j.ijpharm.2004.12.030 ↗
13. Garcia-Fuentes · Eur. J. Pharm. Sci. · 2005 · 25 · 13310.1016/j.ejps.2005.02.008 ↗
14. Müller · Int. J. Pharm. · 2006 · 317 · 8210.1016/j.ijpharm.2006.02.045 ↗
15. Bekerman · J. Pharm. Sci. · 2004 · 93 · 126410.1002/jps.20057 ↗
16. Zhang · Int. J. Pharm. · 2006 · 327 · 15310.1016/j.ijpharm.2006.07.026 ↗
17. Caliceti · Proc. Int. Symp. Control. Release Bioact. Mater. · 2006 · 33 · 383
18. Saraf · Vaccine · 2006 · 24 · 4510.1016/j.vaccine.2005.07.053 ↗
19. Gualbert · Int. J. Pharm. · 2003 · 257 · 6910.1016/S0378-5173(03)00138-8 ↗
20. Almeida · Int. J. Pharm. · 1997 · 149 · 25510.1016/S0378-5173(97)04885-0 ↗
21. Liu · Int. J. Pharm. · 2008 · 356 · 33310.1016/j.ijpharm.2008.01.008 ↗
22. Shive · Adv. Drug Deliv. Rev. · 1997 · 28 · 510.1016/S0169-409X(97)00048-3 ↗
23. Jiang · Adv. Drug Deliv. Rev. · 2005 · 57 · 39110.1016/j.addr.2004.09.003 ↗
24. Zweers Miechel · J. Control. Release · 2004 · 100 · 34710.1016/j.jconrel.2004.09.008 ↗
25. Jain Rajeev · Biomaterials · 2000 · 21 · 247510.1016/S0142-9612(00)00115-0 ↗
26. Wu · Artif. Cells Blood Substit. Immobil. Biotechnol. · 2004 · 32 · 57510.1081/BIO-200039635 ↗
27. Steinberg · Biomaterials · 1995 · 16 · 133910.1016/0142-9612(95)91050-9 ↗
28. Lugtenberg · FEBS Lett. · 1975 · 58 · 25410.1016/0014-5793(75)80272-9 ↗
29. Marks · Clin. Chim. Acta · 1996 · 251 · 1910.1016/0009-8981(96)83704-1 ↗
30. Li · J. Control. Release · 2000 · 68 · 4110.1016/S0168-3659(00)00235-2 ↗
31. Ishington · Adv. Drug Deliv. Rev. · 1996 · 20 · 13110.1016/0169-409X(95)00116-O ↗
32. Han · Colloids Surf. A: Physicochem. Eng. Aspects · 2008 · 315 · 21010.1016/j.colsurfa.2007.08.005 ↗
33. Liu · Int. J. Pharm. · 2007 · 340 · 15310.1016/j.ijpharm.2007.03.009 ↗
34. Deng · J. Control. Release · 1999 · 58 · 12310.1016/S0168-3659(98)00147-3 ↗
35. Müller · Eur. J. Pharm. Biopharm. · 2000 · 50 · 16110.1016/S0939-6411(00)00087-4 ↗
36. Olbrich · J. Nanoparticle Res. · 2002 · 4 · 12110.1023/A:1020159331420 ↗
37. Perez · J. Pharm. Pharmacol. · 2002 · 54 · 30110.1211/0022357021778448 ↗
38. Morel · Eur. J. Pharm. Biopharm. · 1998 · 45 · 15710.1016/S0939-6411(97)00107-0 ↗